{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:49:04Z","timestamp":1789663744501,"version":"4.0.1"},"reference-count":79,"publisher":"Tohoku University Medical Press","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2022]]},"DOI":"10.1620\/tjem.256.197","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T22:11:00Z","timestamp":1647641460000},"page":"197-207","source":"Crossref","is-referenced-by-count":7,"title":["Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR\/Cas Alternatives"],"prefix":"10.1620","volume":"256","author":[{"given":"Irving","family":"Jair Lara-Navarro","sequence":"first","affiliation":[{"name":"Divisi\u00f3n de Gen\u00e9tica, Centro de Investigaci\u00f3n Biom\u00e9dica de Occidente, Instituto Mexicano del Seguro Social"},{"name":"Doctorado en Gen\u00e9tica Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rebeca Jaloma-Cruz","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Gen\u00e9tica, Centro de Investigaci\u00f3n Biom\u00e9dica de Occidente, Instituto Mexicano del Seguro Social"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Asokan, A., Schaffer, D.V. &amp; Samulski, R.J.(2012)  The AAV vector toolkit: poised at the clinical crossroads.  <i>Mol. Ther<\/i>., 20, 699-708.","DOI":"10.1038\/mt.2011.287"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bergmann, T., Ehrke-Schulz, E., Gao, J., Schiwon, M., Schildgen, V., David, S., Schildgen, O. &amp; Ehrhardt, A.(2018)  Designer nuclease-mediated gene correction via homology-directed repair in an in vitro model of canine hemophilia B.  <i>J. Gene Med<\/i>., 20, e3020.","DOI":"10.1002\/jgm.3020"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Blanchette, V.S., Key, N.S., Ljung, L.R., Manco-Johnson, M.J., van den Berg, H.M. &amp; Srivastava, A.; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis (2014)  Definitions in hemophilia: communication from the SSC of the ISTH.  <i>J. Thromb. Haemost<\/i>., 12, 1935-1939.","DOI":"10.1111\/jth.12672"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Chen, H., Shi, M., Gilam, A., Zheng, Q., Zhang, Y., Afrikanova, I., Li, J., Gluzman, Z., Jiang, R., Kong, L.J. &amp; Chen-Tsai, R.Y.(2019)  Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.  <i>Sci. Rep<\/i>., 9, 16838.","DOI":"10.1038\/s41598-019-53198-y"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Chen, J., An, B., Yu, B., Peng, X., Yuan, H., Yang, Q., Chen, X., Yu, T., Wang, L., Zhang, X., Wang, H., Zou, X., Pang, D., Ouyang, H. &amp; Tang, X.(2021)  CRISPR\/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs.  <i>Haematologica<\/i>, 106, 829-837.","DOI":"10.3324\/haematol.2019.224063"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Collins, P., Chalmers, E., Chowdary, P., Keeling, D., Mathias, M., O\u2019Donnell, J., Pasi, K.J., Rangarajan, S. &amp; Thomas, A.(2016)  The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.  <i>Haemophilia<\/i>, 22, 487-498.","DOI":"10.1111\/hae.13013"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Croteau, S.E., Wang, M. &amp; Wheeler, A.P.(2021)  2021 clinical trials update: innovations in hemophilia therapy.  <i>Am. J. Hematol<\/i>., 96, 128-144.","DOI":"10.1002\/ajh.26018"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Doudna, J.A. &amp; Charpentier, E.(2014)  Genome editing. The new frontier of genome engineering with CRISPR-Cas9.  <i>Science<\/i>, 346, 1258096.","DOI":"10.1126\/science.1258096"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Dumont, J.A., Liu, T., Low, S.C., Zhang, X., Kamphaus, G., Sakorafas, P., Fraley, C., Drager, D., Reidy, T., McCue, J., Franck, H.W., Merricks, E.P., Nichols, T.C., Bitonti, A.J., Pierce, G.F., et al.(2012)  Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.  <i>Blood<\/i>, 119, 3024-3030.","DOI":"10.1182\/blood-2011-08-367813"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Ernst, M.P.T., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A.T. &amp; Pijnappel, W.(2020)  Ready for repair? Gene editing enters the clinic for the treatment of human disease.  <i>Mol. Ther. Methods Clin. Dev<\/i>., 18, 532-557.","DOI":"10.1016\/j.omtm.2020.06.022"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Escobar, M., Santagostino, E., Mancuso, M.E., Coppens, M., Balasa, V., Taylor, J.A., Iorio, A. &amp; Negrier, C.(2019)  Switching patients in the age of long-acting recombinant products?  <i>Expert Rev. Hematol<\/i>., 12, 1-13.","DOI":"10.1080\/17474086.2018.1564032"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Evens, H., Chuah, M.K. &amp; VandenDriessche, T.(2018)  Haemophilia gene therapy: from trailblazer to gamechanger .  <i>Haemophilia<\/i>, 24 Suppl 6, 50-59.","DOI":"10.1111\/hae.13494"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Gao, J., Bergmann, T., Zhang, W., Schiwon, M., Ehrke-Schulz, E. &amp; Ehrhardt, A.(2019)  Viral vector-based delivery of CRISPR\/Cas9 and donor DNA for homology-directed repair in an in vitro model for canine hemophilia B.  <i>Mol. Ther. Nucleic Acids<\/i>, 14, 364-376.","DOI":"10.1016\/j.omtn.2018.12.008"},{"key":"14","doi-asserted-by":"crossref","unstructured":"George, L.A. &amp; Fogarty, P.F.(2016)  Gene therapy for hemophilia: past, present and future. <i>Semin. Hematol<\/i>., 53, 46-54.","DOI":"10.1053\/j.seminhematol.2015.10.002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"George, L.A., Sullivan, S.K., Giermasz, A., Rasko, J.E.J., Samelson-Jones, B.J., Ducore, J., Cuker, A., Sullivan, L.M., Majumdar, S., Teitel, J., McGuinn, C.E., Ragni, M.V., Luk, A.Y., Hui, D., Wright, J.F., et al.(2017)  Hemophilia B gene therapy with a high-specific-activity factor IX variant.  <i>N. Engl. J. Med<\/i>., 377, 2215-2227.","DOI":"10.1056\/NEJMoa1708538"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Romero, E., Martinez-Valiente, C., Garcia-Ruiz, C., Vazquez-Manrique, R.P., Cervera, J. &amp; Sanjuan-Pla, A.(2019)  CRISPR to fix bad blood: a new tool in basic and clinical hematology.  <i>Haematologica<\/i>, 104, 881-893.","DOI":"10.3324\/haematol.2018.211359"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Guan, Y., Ma, Y., Li, Q., Sun, Z., Ma, L., Wu, L., Wang, L., Zeng, L., Shao, Y., Chen, Y., Ma, N., Lu, W., Hu, K., Han, H., Yu, Y., et al.(2016)  CRISPR\/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.  <i>EMBO Mol. Med<\/i>., 8, 477-488.","DOI":"10.15252\/emmm.201506039"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Guo, X.L., Chung, T.H., Qin, Y., Zheng, J., Zheng, H., Sheng, L., Wynn, T. &amp; Chang, L.J.(2019)  Hemophilia gene therapy: new development from bench to bed side.  <i>Curr. Gene Ther<\/i>., 19, 264-273.","DOI":"10.2174\/1566523219666190924121836"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Hartmann, R., Feenstra, T., Valentino, L., Dockal, M. &amp; Scheiflinger, F.(2018)  In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. <i>J. Thromb. Haemost<\/i>., 16, 1580-1591.","DOI":"10.1111\/jth.14203"},{"key":"20","unstructured":"He, Q., Wang, H.H., Cheng, T., Yuan, W.P., Ma, Y.P., Jiang, Y.P. &amp; Ren, Z.H.(2017)  Genetic correction and hepatic differentiation of hemophilia B-specific human induced pluripotent stem cells.  <i>Chin. Med. Sci. J<\/i>., 32, 135-144."},{"key":"21","doi-asserted-by":"crossref","unstructured":"Hermans, C. &amp; Dolan, G.(2020)  Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review.  <i>Ther. Adv. Hematol<\/i>., 11, 2040620720966888.","DOI":"10.1177\/2040620720966888"},{"key":"22","doi-asserted-by":"crossref","unstructured":"High, K.H., Nathwani, A., Spencer, T. &amp; Lillicrap, D.(2014)  Current status of haemophilia gene therapy.  <i>Haemophilia<\/i>, 20 Suppl 4, 43-49.","DOI":"10.1111\/hae.12411"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Hu, Z., Zhou, M., Wu, Y., Li, Z., Liu, X., Wu, L. &amp; Liang, D.(2019)  ssODN-mediated in-frame deletion with CRISPR\/Cas9 restores FVIII function in hemophilia A-patient-derived iPSCs and ECs.  <i>Mol. Ther. Nucleic Acids<\/i>, 17, 198-209.","DOI":"10.1016\/j.omtn.2019.05.019"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Huai, C., Jia, C., Sun, R., Xu, P., Min, T., Wang, Q., Zheng, C., Chen, H. &amp; Lu, D.(2017)  CRISPR\/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.  <i>Hum. Genet<\/i>., 136, 875-883.","DOI":"10.1007\/s00439-017-1801-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Iorio, A., Stonebraker, J.S., Chambost, H., Makris, M., Coffin, D., Herr, C. &amp; Germini, F.; Data and Demographics Committee of the World Federation of Hemophilia (2019)  Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries.  <i>Ann. Intern. Med<\/i>., 171, 540-546.","DOI":"10.7326\/M19-1208"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Ivens, I.A., Baumann, A., McDonald, T.A., Humphries, T.J., Michaels, L.A. &amp; Mathew, P.(2013)  PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.  <i>Haemophilia<\/i>, 19, 11-20.","DOI":"10.1111\/j.1365-2516.2012.02931.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A. &amp; Charpentier, E.(2012)  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.  <i>Science<\/i>, 337, 816-821.","DOI":"10.1126\/science.1225829"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Jinek, M., East, A., Cheng, A., Lin, S., Ma, E. &amp; Doudna, J.(2013)  RNA-programmed genome editing in human cells.  <i>Elife<\/i>, 2, e00471.","DOI":"10.7554\/eLife.00471"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., Suzuki, T., Adachi, H., Miyazaki, T., Ishii, S., Kamata-Sakurai, M., et al.(2012)  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.  <i>Nat. Med<\/i>., 18, 1570-1574.","DOI":"10.1038\/nm.2942"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Kleiboer, B., Nielsen, B., Ma, A.D., Abajas, Y., Monroe, D.M. &amp; Key, N.S.(2020)  Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: a single centre case series.  <i>Haemophilia<\/i>, 26, e23-e25.","DOI":"10.1111\/hae.13896"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Kotin, R.M., Linden, R.M. &amp; Berns, K.I.(1992)  Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination.  <i>EMBO J<\/i>., 11, 5071-5078.","DOI":"10.1002\/j.1460-2075.1992.tb05614.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Lieuw, K. (2017)  Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?  <i>J. Blood Med<\/i>., 8, 67-73.","DOI":"10.2147\/JBM.S103796"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Lino, C.A., Harper, J.C., Carney, J.P. &amp; Timlin, J.A.(2018)  Delivering CRISPR: a review of the challenges and approaches.  <i>Drug Deliv<\/i>., 25, 1234-1257.","DOI":"10.1080\/10717544.2018.1474964"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Ljung, R.C.R.(2018)  Prevention and management of bleeding episodes in children with hemophilia.  <i>Paediatr. Drugs<\/i>, 20, 455-464.","DOI":"10.1007\/s40272-018-0307-z"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Lyu, C., Shen, J., Wang, R., Gu, H., Zhang, J., Xue, F., Liu, X., Liu, W., Fu, R., Zhang, L., Li, H., Zhang, X., Cheng, T., Yang, R. &amp; Zhang, L.(2018)  Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.  <i>Stem Cell. Res. Ther<\/i>., 9, 92.","DOI":"10.1186\/s13287-018-0839-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Mahlangu, J., Oldenburg, J., Paz-Priel, I., Negrier, C., Niggli, M., Mancuso, M.E., Schmitt, C., Jimenez-Yuste, V., Kempton, C., Dhalluin, C., Callaghan, M.U., Bujan, W., Shima, M., Adamkewicz, J.I., Asikanius, E., et al.(2018)  Emicizumab prophylaxis in patients who have hemophilia A without inhibitors.  <i>N. Engl. J. Med<\/i>., 379, 811-822.","DOI":"10.1056\/NEJMoa1803550"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Mahlangu, J., Powell, J.S., Ragni, M.V., Chowdary, P., Josephson, N.C., Pabinger, I., Hanabusa, H., Gupta, N., Kulkarni, R., Fogarty, P., Perry, D., Shapiro, A., Pasi, K.J., Apte, S., Nestorov, I., et al.(2014)  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.  <i>Blood<\/i>, 123, 317-325.","DOI":"10.1182\/blood-2013-10-529974"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Makarova, K.S., Wolf, Y.I., Iranzo, J., Shmakov, S.A., Alkhnbashi, O.S., Brouns, S.J.J., Charpentier, E., Cheng, D., Haft, D.H., Horvath, P., Moineau, S., Mojica, F.J.M., Scott, D., Shah, S.A., Siksnys, V., et al.(2020)  Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.  <i>Nat. Rev. Microbiol<\/i>., 18, 67-83.","DOI":"10.1038\/s41579-019-0299-x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Malec, L.M., Croteau, S.E., Callaghan, M.U. &amp; Sidonio, R.F. Jr.(2020)  Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US haemophilia treatment centres.  <i>Haemophilia<\/i>, 26, e128-e129.","DOI":"10.1111\/hae.13943"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E. &amp; Church, G.M.(2013)  RNA-guided human genome engineering via Cas9. <i>Science<\/i>, 339, 823-826.","DOI":"10.1126\/science.1232033"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Mancuso, M.E. &amp; Santagostino, E.(2017)  Outcome of clinical trials with new extended half-life FVIII\/IX concentrates.  <i>J. Clin. Med<\/i>., 6, 39.","DOI":"10.3390\/jcm6040039"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Mannucci, P.M.(2020)  Hemophilia therapy: the future has begun.  <i>Haematologica<\/i>, 105, 545-553.","DOI":"10.3324\/haematol.2019.232132"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Meeks, S.L. &amp; Lacroix-Desmazes, S.(2020)  Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.  <i>Haemophilia<\/i>, 26, 958-965.","DOI":"10.1111\/hae.14123"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Monahan, P.E. (2015)  Gene therapy in an era of emerging treatment options for hemophilia B.  <i>J. Thromb. Haemost<\/i>., 13 Suppl 1, S151-160.","DOI":"10.1111\/jth.12957"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Morfini, M. &amp; Marchesini, E.(2020)  The availability of new drugs for hemophilia treatment.  <i>Expert Rev. Clin. Pharmacol<\/i>., 13, 721-738.","DOI":"10.1080\/17512433.2020.1776109"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Morfini, M. &amp; Rapisarda, C.A.P.(2019)  Safety of recombinant coagulation factors in treating hemophilia.  <i>Expert Opin. Drug Saf<\/i>., 18, 75-85.","DOI":"10.1080\/14740338.2019.1574743"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Nathwani, A.C., Reiss, U.M., Tuddenham, E.G., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., Riddell, A., Pie, J., Rangarajan, S., Bevan, D., Recht, M., et al.(2014)  Long-term safety and efficacy of factor IX gene therapy in hemophilia B.  <i>N. Engl. J. Med<\/i>., 371, 1994-2004.","DOI":"10.1056\/NEJMoa1407309"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Negrier, C. (2016)  Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP)  - advancing the journey.  <i>Thromb. Res<\/i>., 141 Suppl 3, S9-S12.","DOI":"10.1016\/S0049-3848(16)30416-9"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Newsom, S., Parameshwaran, H.P., Martin, L. &amp; Rajan, R.(2021)  The CRISPR-Cas mechanism for adaptive immunity and alternate bacterial functions fuels diverse biotechnologies.  <i>Front. Cell. Infect. Microbiol<\/i>., 10, 619763.","DOI":"10.3389\/fcimb.2020.619763"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Odiba, A.S., Okoro, N.O., Durojaye, O.A. &amp; Wu, Y.(2021)  Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders.  <i>Open Life Sci<\/i>., 16, 431-441.","DOI":"10.1515\/biol-2021-0033"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Oldenburg, J., Mahlangu, J.N., Kim, B., Schmitt, C., Callaghan, M.U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., Valente, N., Asikanius, E., Levy, G.G., Windyga, J. &amp; Shima, M.(2017)  Emicizumab prophylaxis in hemophilia A with inhibitors.  <i>N. Engl. J. Med<\/i>., 377, 809-818.","DOI":"10.1056\/NEJMoa1703068"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Olmedillas L\u00f3pez, S., Garcia-Arranz, M., Garcia-Olmo, D. &amp; Liras, A.(2016)  Preliminary study on non-viral transfection of F9 (factor IX) gene by nucleofection in human adipose-derived mesenchymal stem cells.  <i>PeerJ<\/i>, 4, e1907.","DOI":"10.7717\/peerj.1907"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Park, C.Y., Kim, D.H., Son, J.S., Sung, J.J., Lee, J., Bae, S., Kim, J.H., Kim, D.W. &amp; Kim, J.S.(2015)  Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9.  <i>Cell Stem Cell<\/i>, 17, 213-220.","DOI":"10.1016\/j.stem.2015.07.001"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Park, C.Y., Sung, J.J., Cho, S.R., Kim, J. &amp; Kim, D.W.(2019)  Universal correction of blood coagulation factor VIII in patient-derived induced pluripotent stem cells using CRISPR\/Cas9.  <i>Stem Cell Reports<\/i>, 12, 1242-1249.","DOI":"10.1016\/j.stemcr.2019.04.016"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Pasi, K.J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C.B., Li, M., Pierce, G.F. &amp; Wong, W.Y.(2020)  Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A.  <i>N. Engl. J. Med<\/i>., 382, 29-40.","DOI":"10.1056\/NEJMoa1908490"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Pignani, S., Zappaterra, F., Barbon, E., Follenzi, A., Bovolenta, M., Bernardi, F., Branchini, A. &amp; Pinotti, M.(2019)  Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts.  <i>Biochim. Biophys. Acta Gene. Regul. Mech<\/i>., 1862, 619-624.","DOI":"10.1016\/j.bbagrm.2019.04.002"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Pipe, S.W. &amp; Selvaraj, S.R.(2019)  Gene editing in hemophilia: a \u201cCRISPR\u201d choice? <i>Blood<\/i>, 133, 2733-2734.","DOI":"10.1182\/blood.2019001180"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Powell, J.S., Josephson, N.C., Quon, D., Ragni, M.V., Cheng, G., Li, E., Jiang, H., Li, L., Dumont, J.A., Goyal, J., Zhang, X., Sommer, J., McCue, J., Barbetti, M., Luk, A., et al.(2012)  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.  <i>Blood<\/i>, 119, 3031-3037.","DOI":"10.1182\/blood-2011-09-382846"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Preijers, T., Bukkems, L., van Spengler, M., Leebeek, F., Cnossen, M. &amp; Mathot, R.(2021)  In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.  <i>Eur. J. Clin. Pharmacol<\/i>., 77, 1193-1200.","DOI":"10.1007\/s00228-021-03111-2"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Santagostino, E., Negrier, C., Klamroth, R., Tiede, A., Pabinger-Fasching, I., Voigt, C., Jacobs, I. &amp; Morfini, M.(2012)  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)  in hemophilia B patients.  <i>Blood<\/i>, 120, 2405-2411.","DOI":"10.1182\/blood-2012-05-429688"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Schulte, S. (2013)  Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.  <i>Thromb. Res<\/i>., 131 Suppl 2, S2-6.","DOI":"10.1016\/S0049-3848(13)70150-6"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Shapiro, A., Chaudhury, A., Wang, M., Escobar, M., Tsao, E., Barnowski, C., Feng, J., Jain, N. &amp; Quon, D.V.(2020)  Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc)  for up to 5 years.  <i>Haemophilia<\/i>, 26, 975-983.","DOI":"10.1111\/hae.14152"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Shi, Q., Mattson, J.G., Fahs, S.A., Geurts, A.M., Weiler, H. &amp; Montgomery, R.R.(2020)  The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.  <i>Blood Adv<\/i>., 4, 55-65.","DOI":"10.1182\/bloodadvances.2019000944"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Shi, X., Kitano, A., Jiang, Y., Luu, V., Hoegenauer, K.A. &amp; Nakada, D.(2018)  Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells.  <i>Exp. Hematol<\/i>., 64, 33-44 e35.","DOI":"10.1016\/j.exphem.2018.04.009"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Stephens, C.J., Lauron, E.J., Kashentseva, E., Lu, Z.H., Yokoyama, W.M. &amp; Curiel, D.T.(2019)  Long-term correction of hemophilia B using adenoviral delivery of CRISPR\/Cas9.  <i>J. Control. Release<\/i>, 298, 128-141.","DOI":"10.1016\/j.jconrel.2019.02.009"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Sung, J.J., Park, C.Y., Leem, J.W., Cho, M.S. &amp; Kim, D.W.(2019)  Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs.  <i>Exp. Mol. Med<\/i>., 51, 1-9.","DOI":"10.1038\/s12276-019-0243-1"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Sung, J.J., Park, S., Choi, S.H., Kim, J., Cho, M.S. &amp; Kim, D.W.(2020)  Generation of a gene edited hemophilia A patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR\/Cas9.  <i>Stem Cell Res<\/i>., 48, 101948.","DOI":"10.1016\/j.scr.2020.101948"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Swierczewska, M., Lee, K.C. &amp; Lee, S.(2015)  What is the future of PEGylated therapies?  <i>Expert Opin. Emerg. Drugs<\/i>, 20, 531-536.","DOI":"10.1517\/14728214.2015.1113254"},{"key":"69","doi-asserted-by":"crossref","unstructured":"VandenDriessche, T. &amp; Chuah, M.K.(2017)  Hemophilia gene therapy: ready for prime time?  <i>Hum. Gene Ther<\/i>., 28, 1013-1023.","DOI":"10.1089\/hum.2017.116"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Wang, L., Yang, Y., Breton, C.A., White, J., Zhang, J., Che, Y., Saveliev, A., McMenamin, D., He, Z., Latshaw, C., Li, M. &amp; Wilson, J.M.(2019)  CRISPR\/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice.  <i>Blood<\/i>, 133, 2745-2752.","DOI":"10.1182\/blood.2019000790"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Wang, Q., Zhong, X., Li, Q., Su, J., Liu, Y., Mo, L., Deng, H. &amp; Yang, Y.(2020)  CRISPR-Cas9-mediated in vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice.  <i>Mol. Ther. Methods Clin. Dev<\/i>., 18, 520-531.","DOI":"10.1016\/j.omtm.2020.06.025"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhao, J., Duan, N., Liu, W., Zhang, Y., Zhou, M., Hu, Z., Feng, M., Liu, X., Wu, L., Li, Z. &amp; Liang, D.(2018)  Paired CRISPR\/Cas9 nickases mediate efficient site-specific integration of F9 into rDNA locus of mouse ESCs.  <i>Int. J. Mol. Sci<\/i>., 19, 3035.","DOI":"10.3390\/ijms19103035"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Ward, P. &amp; Walsh, C.E.(2016)  Current and future prospects for hemophilia gene therapy.  <i>Expert Rev. Hematol<\/i>., 9, 649-659.","DOI":"10.1080\/17474086.2016.1182859"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Weyand, A.C. &amp; Pipe, S.W.(2019)  New therapies for hemophilia. <i>Blood<\/i>, 133, 389-398.","DOI":"10.1182\/blood-2018-08-872291"},{"key":"75","unstructured":"World Federation of Hemophilia (2019)  Report on the Annual Global Survey 2019. https:\/\/elearning.wfh.org\/resource\/report-on-the-annual-global-survey-2019\/ [Accessed: September 13, 2021]."},{"key":"76","doi-asserted-by":"crossref","unstructured":"Wu, W.Y., Lebbink, J.H.G., Kanaar, R., Geijsen, N. &amp; van der Oost, J.(2018)  Genome editing by natural and engineered CRISPR-associated nucleases.  <i>Nat. Chem. Biol<\/i>., 14, 642-651.","DOI":"10.1038\/s41589-018-0080-x"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Young, G., Liesner, R., Chang, T., Sidonio, R., Oldenburg, J., Jimenez-Yuste, V., Mahlangu, J., Kruse-Jarres, R., Wang, M., Uguen, M., Doral, M.Y., Wright, L.Y., Schmitt, C., Levy, G.G., Shima, M., et al.(2019)  A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.  <i>Blood<\/i>, 134, 2127-2138.","DOI":"10.1182\/blood.2019001869"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O., Slaymaker, I.M., Makarova, K.S., Essletzbichler, P., Volz, S.E., Joung, J., van der Oost, J., Regev, A., Koonin, E.V. &amp; Zhang, F.(2015)  Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.  <i>Cell<\/i>, 163, 759-771.","DOI":"10.1016\/j.cell.2015.09.038"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Zhang, J.P., Cheng, X.X., Zhao, M., Li, G.H., Xu, J., Zhang, F., Yin, M.D., Meng, F.Y., Dai, X.Y., Fu, Y.W., Yang, Z.X., Arakaki, C., Su, R.J., Wen, W., Wang, W.T., et al.(2019)  Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse.  <i>Genome Biol<\/i>., 20, 276.","DOI":"10.1186\/s13059-019-1907-9"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/256\/3\/256_256.197\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:19:11Z","timestamp":1715231951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/256\/3\/256_256.197\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.256.197","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"256.197"}}